Infantile digital fibromatosis

Last updated
Infantile digital fibromatosis
Other namesInclusion body fibromatosis, Infantile digital myofibroblastoma, Reye tumor, Reye's tumor
Specialty Pediatrics, Dermatology
Usual onsetTypically at birth or infancy
CausesUnknown
Prognosis Excellent
FrequencyRare

Infantile digital fibromatosis (IDF), also termed inclusion body fibromatosis, Reye tumor, or Reye's tumor, usually occurs as a single, small, asymptomatic, nodule in the dermis on a finger or toe [1] of infants and young children. [2] IMF is a rare disorder with approximately 200 cases reported in the medical literature as of 2021. [3] The World Health Organization in 2020 classified these nodules as a specific benign tumor type in the category of fibroblastic and myofibroblastic tumors. [4] IDF was first described by the Australian pathologist, Douglas Reye, in 1965. [5]

Contents

IDF consists of an overgrowth of spindle-shaped cells in a collagen fiber-rich background located in the dermis (i.e. the layer of skin between the epidermis and subcutaneous tissue) but may extend into the subcutaneous tissue. These spindle-shaped cells contain distinctive inclusion bodies within their cytoplasm that greatly help in distinguishing IDF from other fibrous skin diseases. These inclusions are composed of densely packed vimentin and actin filaments. [6]

IDF lesions are usually painless and have a tendency to regress spontaneously. Consequently, the current recommended treatment for IDF nodules is conservative observation. [3] If the lesions cause local deformities and/or functional impairments or continue to increase in size over long observation periods, surgical removal is recommended. However, surgically removed IDF lesions have had high rates of recurrence and this surgery may cause post-operative digital deformities. [6]

Presentation

IDF typically presents as a solitary painless, smooth, flesh-colored to red, dome-shaped nodule located on the dorsal or lateral aspect of a finger or toe but sparing the thumb or great toe; [3] they occur principally in the first two years of life with about one-third of cases having a lesion since birth. [6] However: 1) lesions with appearances similar to, and diagnosed as, IPF have been described in extra digital sites such as the arm, breast, tongue, thigh, [3] and chest; [6] 2) unusual cases have presented with multiple lesions, i.e. 2–3, uncommonly 7–15, and one case with 74 lesions in a 2018 review study; [7] 3) cases have been reported in children up to the age 10 and one case was reported in a 52-year-old adult; [8] 4) the lesions are typically smaller than 2 cm in maximum diameter [3] but rarely have been tumor-sized, e.g. 4.5 cm; [6] 5) the lesions, particularly when larger-sized, may be painful and/or compromise the functions of nearby joints and digits; [7] and 6) the lesions occasionally invade the periosteum and erode a nearby bone. [6]

Pathology

Microscopic histopathological analyses of appropriately dye-stained IDF tissues typically show a non-encapsulated small tumor composed of bundles of uniform spindle-shaped cells that combine physical features of fibroblasts (the most common cell type in connective tissue) with those of myofibroblasts (contractile, spindle-shaped cells that are identifiable by their expression of α-smooth muscle actin) in a background of collagen fibers. [3] In hematoxylin and eosin-stained tissues, the spindle-shaped cells have pale eosinophilic (i.e. red or pink due to uptake of eosin) cytoplasm with plump and elongated nuclei composed of granulated (i.e. having many small, distinct parts) chromatin. The most pathognomonic (i.e. indicative of a particular disease) feature of these cells is the presence of cytoplasmic perinuclear inclusion bodies which usually are small, round, pale pink bodies on hematoxylin and eosin staining that often indent their parent cells' nuclei. These inclusions are composed of densely packed vimentin and actin filaments. Newer tumors show relatively abundant inclusion bodies and scarce collagen fibers while older tumors show few or no detectable inclusion bodies and abundant collagen fibers. Immunohistochemical analyses show that the spindle-shaped cells typically express α-smooth muscle actin, calponin, desmin, and CD99 proteins [8] but not S100 protein or glial fibrillary acidic protein. [6]

Diagnosis

The diagnosis of IDF is usually based on its presentation in newborn or young infants and biopsy or fine needle aspirate analyses of the tumors' pathology. [7] These analyses should show the presence of spindle-shaped cells bearing eosinophilic paranuclear inclusions consisting of actin and vimentin filaments, which, if necessary, can be confirmed by immunofluorescence staining of the filaments. [6] Inclusions may not be evident in older lesions stained with hematoxylin and eosin but may be apparent when stained with other reagents such as the Masson's trichrome stain, [6] phosphotungstic acid-haematoxylin stain, elastic Van Gieson's stain, or Lendrum's phloxine-tartrazine stain. [6] Demonstration of these filaments is not necessary for a diagnosis of IMF if the clinical picture and other histological findings are consistent with the disorder. [7] Findings of one or a few usually small lesions centered in the dermis of a digit consisting of spindle-shaped cells and expressing α-smooth muscle actin, desmin, and calponin proteins would support the diagnosis of IDF. [8]

Infantile myofibromatosis (IMF) is, like IDF, a disease in which benign tumors develop primarily in the fingers and toes of newborns and infants and consists of spindle-shaped cells in a collagen fibrous background. IDF was once regarded as a sub-type of infantile myofibromatosis. However, IMF tumors can be far more aggressive than IDF lesions and consist of cells that do not have paranuclear inclusions. [2] The World Health Organization (2020) classification includes IPF but not IMF as a tumor in the category of benign fibroblastic and myofibroblastic tumors. [4]

Treatment

Infantile digital fibroma lesions were once thought to be potentially malignant and therefore treated with surgical excision and even digital amputations. [8] Currently, these tumors are known to be benign, [4] may spontaneously regress, and often recur after surgical removal. [8] Consequently, IDF lesions are usually treated by a watchful waiting observation approach with surgical resections limited to cases with functional impairment, [3] significant symptoms, or progressive, long-term growth. [7] Alternate or supplemental treatments used to treat IDF include injection of the glucocorticoid, triamcinolone, or the chemotherapy drug, 5-fluorouracil, directly into the lesions. [3] Since these injection treatments have not been evaluated in large studies to date, surgical resection is the most accepted treatment of highly symptomatic or progressively enlarging IDF lesions. [7] Overall, the prognosis for IDF is excellent. [3]

See also

Related Research Articles

<span class="mw-page-title-main">Thymoma</span> Medical condition

A thymoma is a tumor originating from the epithelial cells of the thymus that is considered a rare malignancy. Thymomas are frequently associated with neuromuscular disorders such as myasthenia gravis; thymoma is found in 20% of patients with myasthenia gravis. Once diagnosed, thymomas may be removed surgically. In the rare case of a malignant tumor, chemotherapy may be used.

<span class="mw-page-title-main">Fibrosarcoma</span> Medical condition

Fibrosarcoma is a malignant mesenchymal tumour derived from fibrous connective tissue and characterized by the presence of immature proliferating fibroblasts or undifferentiated anaplastic spindle cells in a storiform pattern. Fibrosarcomas mainly arise in people between the ages of 25 and 79. It originates in fibrous tissues of the bone and invades long or flat bones such as the femur, tibia, and mandible. It also involves the periosteum and overlying muscle.

<span class="mw-page-title-main">Nodular fasciitis</span> Medical condition

Nodular fasciitis (NF) is a benign, soft tissue tumor composed of myofibroblasts that typically occurs in subcutaneous tissue, fascia, and/or muscles. The literature sometimes titles rare NF variants according to their tissue locations. The most frequently used and important of these are cranial fasciitis and intravascular fasciitis. In 2020, the World Health Organization classified nodular fasciitis as in the category of benign fibroblastic/myofibroblastic tumors. NF is the most common of the benign fibroblastic proliferative tumors of soft tissue.

Giant cell fibroblastoma (GCF) is a rare type of soft-tissue tumor marked by painless nodules in the dermis and subcutaneous tissue. These tumors may come back after surgery, but they do not spread to other parts of the body. They occur mostly in boys. GCF tumor tissues consist of bland spindle-shaped or stellate-shaped cells interspersed among multinucleated giant cells.

<span class="mw-page-title-main">Angiofibroma</span> Medical condition

Angiofibroma (AGF) is a descriptive term for a wide range of benign skin or mucous membrane lesions in which individuals have:

  1. benign papules, i.e. pinhead-sized elevations that lack visible evidence of containing fluid;
  2. nodules, i.e. small firm lumps usually >0.1 cm in diameter; and/or
  3. tumors, i.e. masses often regarded as ~0.8 cm or larger.

Fibromatosis colli (FMC), also termed sternocleidomastoid tumor of infancy, pseudotumor of infancy, and infancy sternocleidomastoid pseudotumor, is an uncommon, congenital tumor in one of the two sternocleidomastoid neck muscles although rare cases have presented with a FMC tumor in both sternocleidomastoid muscles. A tumor is here defined as a growth of tissue that is not coordinated with the normal surrounding tissue and persists in growing even if the original trigger for its growth is removed. FMC tumors are benign growths that may cause disfigurements but are not cancers and do not metastasize to distant tissues.

Fibrous hamartoma of infancy (FHI) is a rare, typically painless, benign tumor that develops in the subcutaneous tissues of the axilla, arms, external genitalia, or, less commonly, various other areas. It is diagnosed in children who are usually less than 2 years old or, in up to 20% of cases, develops in utero and is diagnosed in an infant at birth.

Infantile myofibromatosis (IMF) is a rare tumor found in 1 in 150,000 to 1 in 400,000 live births. It is nonetheless the most common tumor derived from fibrous connective tissue that occurs primarily in infants and young children. IMF tumors are benign in the sense that they do not metastasize to distant tissues although when occurring in the viscera, i.e. internal organs, carry guarded to poor prognoses and can be life-threatening, particularly in newborns and young infants. The condition was first described by Arthur Purdy Stout as congenital generalized fibromatosis – in which he coined the word fibromatosis – in 1954.

Diffuse infantile fibromatosis is a rare condition affecting infants during the first three years of life. This condition is a multicentric infiltration of muscle fibers with fibroblasts resembling those seen in aponeurotic fibromas, presenting as lesions and tumors confined usually to the muscles of the arms, neck, and shoulder area Diffuse infantile fibromatosis is characterized by fast growing benign tumors. This disorder is known to be caused by mutations in germline variants, PDGFRB and NOTCH3, which may be generationally-inherited through autosomal dominant and recessive traits. Although diffuse infantile fibromatosis is classified as benign, it can still lead to life-threatening complications and damage other organs.

<span class="mw-page-title-main">Koenen's tumor</span> Medical condition

Koenen's tumor (KT), also commonly termed periungual angiofibroma, is a subtype of the angiofibromas. Angiofibromas are benign papule, nodule, and/or tumor lesions that are separated into various subtypes based primarily on the characteristic locations of their lesions. KTs are angiofibromas that develop in and under the toenails and/or fingernails. KTs were once considered as the same as another subtype of the angiofibromas viz., acral angiofibromas. While the literature may still sometimes regard KTs as acral angiofibromas, acral angiofibromas are characteristically located in areas close to but not in the toenails and fingernails as well as in the soles of the feet and palms of the hands. KTs are here regarded as distinct from acral angiofibromas.

<span class="mw-page-title-main">Fibroma of tendon sheath</span> Medical condition

Fibroma of tendon sheath is a benign tumor that presents as a small subcutaneous nodule that slowly increases in size. The tumors often have a multinodular growth pattern, with individual nodules being composed of bland, slender, spindle-shaped cells (myofibroblasts) in a dense, fibrous matrix.” A common microscopic finding is the presence of elongated, slit-like blood vessels. The lesions nearly always arise in the distal portions of the extremities. They often occur on the fingers, hands, toes, or feet. Although they are benign, they may recur in up to 40% of cases.

Nuchal-type fibroma is a rare benign proliferation involving the dermis and subcutaneous tissues, that is a collection of dense, hypocellular bundles of collagen with entrapped adipocytes and increased numbers of small nerves. It is no longer called a nuchal fibroma, but instead a "nuchal-type fibroma" since it develops in other anatomic sites. There is no known etiology. The World Health Organization in 2020 classified nuchal fibromas as a specific tumor form in the category of benign fibroblastic and myofibroblastic tumors.

<span class="mw-page-title-main">Ovarian fibroma</span> Medical condition

The ovarian fibroma, also fibroma, is a benign sex cord-stromal tumour.

<span class="mw-page-title-main">Low-grade fibromyxoid sarcoma</span> Medical condition

Low-grade fibromyxoid sarcoma (LGFMS) is a rare type of low-grade sarcoma first described by H. L. Evans in 1987. LGFMS are soft tissue tumors of the mesenchyme-derived connective tissues; on microscopic examination, they are found to be composed of spindle-shaped cells that resemble fibroblasts. These fibroblastic, spindle-shaped cells are neoplastic cells that in most cases of LGFMS express fusion genes, i.e. genes composed of parts of two different genes that form as a result of mutations. The World Health Organization (2020) classified LGFMS as a specific type of tumor in the category of malignant fibroblastic and myofibroblastic tumors.

<span class="mw-page-title-main">Mammary-type myofibroblastoma</span> Medical condition

Mammary-type myofibroblastoma (MFB), also named mammary and extramammary myofibroblastoma, was first termed myofibrolastoma of the breast, or, more simply, either mammary myofibroblastoma (MMFB) or just myofibroblastoma. The change in this terminology occurred because the initial 1987 study and many subsequent studies found this tumor only in breast tissue. However, a 2001 study followed by numerous reports found tumors with the microscopic histopathology and other key features of mammary MFB in a wide range of organs and tissues. Further complicating the issue, early studies on MFB classified it as one of various types of spindle cell tumors that, except for MFB, were ill-defined. These other tumors, which have often been named interchangeably in different reports, are: myelofibroblastoma, benign spindle cell tumor, fibroma, spindle cell lipoma, myogenic stromal tumor, and solitary stromal tumor. Finally, studies suggest that spindle cell lipoma and cellular angiofibroma are variants of MFB. Here, the latter two tumors are tentatively classified as MFB variants but otherwise MFB is described as it is more strictly defined in most recent publications. The World Health Organization in 2020 classified mammary type myofibroblastoma tumors and myofibroblastoma tumors as separate tumor forms within the category of fibroblastic and myofibroblastic tumors.

Fibroblastic and myofibroblastic tumors (FMTs) develop from the mesenchymal stem cells which differentiate into fibroblasts and/or the myocytes/myoblasts that differentiate into muscle cells. FMTs are a heterogeneous group of soft tissue neoplasms. The World Health Organization (2020) defined tumors as being FMTs based on their morphology and, more importantly, newly discovered abnormalities in the expression levels of key gene products made by these tumors' neoplastic cells. Histopathologically, FMTs consist of neoplastic connective tissue cells which have differented into cells that have microscopic appearances resembling fibroblasts and/or myofibroblasts. The fibroblastic cells are characterized as spindle-shaped cells with inconspicuous nucleoli that express vimentin, an intracellular protein typically found in mesenchymal cells, and CD34, a cell surface membrane glycoprotein. Myofibroblastic cells are plumper with more abundant cytoplasm and more prominent nucleoli; they express smooth muscle marker proteins such as smooth muscle actins, desmin, and caldesmon. The World Health Organization further classified FMTs into four tumor forms based on their varying levels of aggressiveness: benign, intermediate, intermediate, and malignant.

Lipofibromatosis-like neural tumor (LPF-NT) is an extremely rare soft tissue tumor first described by Agaram et al in 2016. As of mid-2021, at least 39 cases of LPF-NT have been reported in the literature. LPF-NT tumors have several features that resemble lipofibromatosis (LPF) tumors, malignant peripheral nerve sheath tumors, spindle cell sarcomas, low-grade neural tumors, peripheral nerve sheath tumors, and other less clearly defined tumors; Prior to the Agaram at al report, LPF-NTs were likely diagnosed as variants or atypical forms of these tumors. The analyses of Agaram at al and subsequent studies uncovered critical differences between LPF-NT and the other tumor forms which suggest that it is a distinct tumor entity differing not only from lipofibromatosis but also the other tumor forms.

Cellular angiofibroma (CAF) is a rare, benign tumor of superficial soft tissues that was first described by M. R. Nucci et al. in 1997. These tumors occur predominantly in the distal parts of the female and male reproductive systems, i.e. in the vulva-vaginal and inguinal-scrotal areas, respectively, or, less commonly, in various other superficial soft tissue areas throughout the body. CAF tumors develop exclusively in adults who typically are more than 30 years old.

Angiofibroma of soft tissue (AFST), also termed angiofibroma, not otherwise specified, is a recently recognized and rare disorder that was classified in the category of benign fibroblastic and myofibroblastic tumors by the World Health Organization in 2020. An AFST tumor is a neoplasm that was first described by A. Mariño-Enríquez and C.D. Fletcher in 2012.

Gardner fibroma (GF) is a benign fibroblastic tumor. GF tumors typically develop in the dermis and adjacent subcutaneous tissue lying just below the dermis. These tumors typically occur on the back, abdomen, and other superficial sites but in rare cases have been diagnoses in internal sites such as the retroperitoneum and around the large blood vessels in the upper thoracic cavity. The World Health Organization, 2020, classified Gardner fibroma as a benign tumor in the category of fibroblastic and myofibroblastic tumors.

References

  1. ↑ Freedberg, et al. (2003). Fitzpatrick's Dermatology in General Medicine. (6th ed.). Page 989. McGraw-Hill. ISBN   0-07-138076-0.
  2. 1 2 Laskin WB, Miettinen M, Fetsch JF (January 2009). "Infantile digital fibroma/fibromatosis: a clinicopathologic and immunohistochemical study of 69 tumors from 57 patients with long-term follow-up". The American Journal of Surgical Pathology. 33 (1): 1–13. doi:10.1097/PAS.0b013e3181788533. PMID   18830128. S2CID   30315278.
  3. 1 2 3 4 5 6 7 8 9 Agnihotri MA, Sathe PA (2021). "Inclusion body fibromatosis - A report of four cases and review of literature". Journal of Postgraduate Medicine. 67 (1): 24–26. doi: 10.4103/jpgm.JPGM_774_20 . PMC   8098864 . PMID   33565473.
  4. 1 2 3 Sbaraglia M, Bellan E, Dei Tos AP (April 2021). "The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives". Pathologica. 113 (2): 70–84. doi:10.32074/1591-951X-213. PMC   8167394 . PMID   33179614.
  5. ↑ REYE RD (September 1965). "Recurring Digital Fibrous Tumors of Childhood". Archives of Pathology. 80: 228–31. PMID   14322942.
  6. 1 2 3 4 5 6 7 8 9 10 Adegoke OO, Ajao AE, Ano-Edward GH (December 2020). "Congenital infantile digital fibromatosis: a case report and review of the literature". African Health Sciences. 20 (4): 1865–1869. doi:10.4314/ahs.v20i4.42. PMC   8351811 . PMID   34394250.
  7. 1 2 3 4 5 6 Eypper EH, Lee JC, Tarasen AJ, Weinberg MH, Adetayo OA (2018). "An Algorithmic Approach to the Management of Infantile Digital Fibromatosis: Review of Literature and a Case Report". ePlasty. 18: e19. PMC   5950536 . PMID   29780440.
  8. 1 2 3 4 5 Marks E, Ewart M (October 2016). "Infantile Digital Fibroma: A Rare Fibromatosis". Archives of Pathology & Laboratory Medicine. 140 (10): 1153–6. doi: 10.5858/arpa.2015-0492-RS . PMID   27684985.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.